secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010480
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks terminates CFO, reports ~$270.6M cash; new COO and CMO appointed
--------------------------------------------------------------------------

- CFO Leone Patterson terminated without cause Jan 9; CEO Kenneth Galbraith appointed interim CFO.
- Preliminary cash $270.6M as of Dec 31, 2025; expects $440M milestones from Ziihera approvals in US/EU/Japan/China.
- $125M share repurchase plan announced Nov 2025; cash runway guided beyond 2028.
- Mark Hollywood promoted to COO (base salary $525K); Brian Cherry appointed Class II director.
- CMO Jeffrey Smith retiring Jan 31; Sabeen Mekan appointed CMO effective Feb 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526010480/0001193125-26-010480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526010480/d97670d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer